Osivax Reports Phase 2b Influenza Vaccine Trial Results, Pursues Combination Approach

Osivax has released Phase 2b trial results for its influenza vaccine candidate, OVX836. While the trial did not meet its primary efficacy endpoint, it demonstrated consistent efficacy for a nucleoprotein-based vaccine against major influenza A subtypes and showed a favorable safety profile. These findings support further development of OVX836 in combination with existing seasonal vaccines to enhance protection, with strategic collaborations already underway.